4-(溴甲基)-2,6-二甲基吡啶 | 79313-02-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-(溴甲基)-2,6-二甲基吡啶
• 英文名称: 4-(bromomethyl)-2,6-dimethylpyridine
• CAS: 79313-02-3
• 化学式: C₈H₁₀BrN
• 分子量: 200.078
• InChiKey: JTXKZBVTKKMCEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-(溴甲基)-2,6-二甲基吡啶 在 potassium tert-butylate 、 羟胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 、 叔丁醇 为溶剂， 反应 17.0h， 生成 (R)-2-[7-(2,6-Dimethyl-pyridin-4-ylmethoxy)-1,1-dioxo-1,3,4,5-tetrahydro-1λ⁶-benzo[f][1,2,5]thiadiazepin-2-yl]-N-hydroxy-propionamide
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of Benzothiadiazepine Hydroxamates as Selective Tumor Necrosis Factor-α Converting Enzyme Inhibitors

  摘要：

  Elevated levels of tumor necrosis factor-alpha (TNF-alpha) have been associated with several inflammatory diseases, and therefore, strategies for its suppression have become important targets in drug discovery. Our efforts to suppress TNF-alpha have centered on the inhibition of TNF-alpha converting enzyme (TACE) through the use of hydroxamate inhibitors. Starting from broad-spectrum matrix metalloproteinase (MMP) inhibitors, we have designed and synthesized novel benzothiadiazepines as potent and selective TACE inhibitors. The benzothiadiazepines were synthesized with variation in P1 and P1' in order to effect potency and selectivity. The inhibitors were evaluated versus porcine TACE (pTACE), and the initial selectivity was assessed with counterscreens of MMP-1, -2, and -9. Several potent and selective inhibitors were discovered with compound 41 being the most active against pTACE (K-i = 5 nM) while still maintaining good selectivity versus the MMP's (at least 75-fold). Most compounds were assessed in the human peripheral blood mononuclear cell assay (PBMC) and the human whole blood assay (WBA) to determine their ability to suppress TNF-alpha. Compound 32 was the most potent compound in the PBMC assay (IC50 = 0.35 muM), while compound 62 was the most active in the WBA (IC50 = 1.4 muM).

  DOI：

  10.1021/jm020475w
• 作为产物：
  描述：

  2,6-二甲基-3-羟甲基吡啶 在 polystyrene supported triphenylphosphine 、 四溴化碳 作用下， 以 氯仿 为溶剂， 反应 0.33h， 生成 4-(溴甲基)-2,6-二甲基吡啶
  参考文献：
  名称：

  [EN] N-SULFONYLPIPERIDINES AS METALLOPROTEINASE INHIBITORS (TACE)
  [FR] N-SULFONYLPIPERIDINES UTILISES COMME INHIBITEURS DE METALLOPROTEINASE (TACE) (ENZYME DE CONVERSION DU FACTEUR DE NECROSE TUMORALE DOLLAR G(A))

  摘要：

  式（1）中的化合物，其中Z为 -CONR15OH 或 -N(OH)CHO，X为 -(CR9R10)t-Q-(CR11R12)u-（其中t和u独立取0或1，但t和u不能同时为0）；是金属蛋白酶抑制剂，特别是TACE。

  公开号：

  WO2004006925A1

文献信息

• [EN] PROCESS FOR PREPARATION OF OPTICALLY ENRICHED ISOXAZOLINES<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ISOXAZOLINES OPTIQUEMENT ENRICHIES
  申请人：BASF SE

  公开号：WO2021197880A1

  公开（公告）日：2021-10-07

  The invention relates to a process for preparing optically enriched isoxazoline compounds of formula (I), formula (I), wherein the variables are as defined in the specification, and the shown enantiomer has at least 55% ee; by oxo-Michael addition of hydroxyl amine or its salt to an enone of formula (II), formula (II), wherein the variables have the meanings given for formula (I), in the presence of a catalyst of formula (III), formula (III), and a base, the invention furthermore relates to novel compounds of formula (III).

  本发明涉及一种用于制备光学富集异恶唑啉化合物公式（I）的过程，公式（I），其中变量如说明书中所定义，并且所示对映体至少具有55%的ee；通过羟基胺或其盐的氧代-Michael加成到公式（II）的烯酮上，公式（II），其中变量具有如公式（I）所给出的含义，在公式（III）的催化剂和碱的存在下，本发明还涉及新型公式（III）的化合物。
• [EN] BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS<br/>[FR] DÉRIVÉS DE BENZOXAZINONE POUR TRAITER DES TROUBLES INDUITS PAR GLYTL
  申请人：GLAXO GROUP LTD

  公开号：WO2011012622A1

  公开（公告）日：2011-02-03

  The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.

  本发明涉及苯并噁唑酮衍生物，其制备方法，含有它们的药物组合物和药物，以及它们在治疗由GlyT1介导的疾病中的应用，包括神经系统和神经精神疾病，特别是精神病、痴呆或注意力缺陷障碍。
• [EN] PYRROLIDINE AND BICYCLOHETEROARYL CONTAINING OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA CONTENANT DE LA PYRROLIDINE ET DE LA BICYCLOHÉTÉROARYLE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021094312A1

  公开（公告）日：2021-05-20

  The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.

  本发明涉及O-GIcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病，如tau病变，特别是阿尔茨海默病或进行性上行性麻痹；以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩侧索硬化或额颞叶痴呆；或α-突触核蛋白病，特别是帕金森病，由帕金森病引起的痴呆（或由帕金森病引起的神经认知障碍），具有Lewy小体的痴呆，多系统萎缩，或由高雪氏病引起的α-突触核蛋白病。
• [EN] MONOCYCLIC OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA MONOCYCLIQUE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018109202A1

  公开（公告）日：2018-06-21

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，用于制备这类化合物和组合物的方法，以及这类化合物和组合物在抑制OGA有益的疾病的预防和治疗中的用途，例如tau病变，特别是阿尔茨海默病或进行性上核性麻痹症；以及伴有tau病理的神经退行性疾病，特别是由C9ORF72突变引起的肌萎缩侧索硬化症或前颞叶痴呆症。
• [EN] N-SULFONYLPIPERIDINES AS METALLOPROTEINASE INHIBITORS (TACE)<br/>[FR] N-SULFONYLPIPERIDINES UTILISES COMME INHIBITEURS DE METALLOPROTEINASE (TACE) (ENZYME DE CONVERSION DU FACTEUR DE NECROSE TUMORALE DOLLAR G(A))
  申请人：ASTRAZENECA AB

  公开号：WO2004006925A1

  公开（公告）日：2004-01-22

  Compounds of formula (1), wherein Z is -CONR15OH or -N(OH)CHO and X is -(CR9R10)t-Q-(CR11R12)u- (where t and u are independently 0 or 1 with the proviso that t and u cannot both be 0);are inhibitors of metalloproteinases and in particular TACE.

  式（1）中的化合物，其中Z为 -CONR15OH 或 -N(OH)CHO，X为 -(CR9R10)t-Q-(CR11R12)u-（其中t和u独立取0或1，但t和u不能同时为0）；是金属蛋白酶抑制剂，特别是TACE。